Monthly archive
4 carefully sourced stories published during this month.
Latest GLP-1 news30 September 2026
McDonald’s says GLP-1 use is changing what some customers want and is exploring smaller, protein-focused choices including bowls, egg bites, grilled chicken and wraps.
Read the sourced summary30 September 2026
Detailed Phase 3 results from the 1,152-person TRIUMPH-2 trial report up to 20.8% average weight loss and a 1.6-percentage-point A1C reduction with retatrutide in adults with type 2 diabetes and obesity or overweight.
Read the sourced summary10 September 2026
Novo Nordisk has reported the first topline results from its phase 3 STEP Young trial of semaglutide in children aged 6–11. We examine the 40.4% headline, the trial design and the important evidence still missing.
Read the sourced summary2 September 2026
A new Annals of Internal Medicine review brings together 38 randomized GLP-1 and co-agonist trials in adults without diabetes. We examine the weight-loss figures, safety findings and limits of cross-trial rankings.
Read the sourced summaryEvery published evidence summary remains available in the archive.
